Spebrutinib besylate
Based on 17 publication(s) in Google Scholar
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays.
For research use only. We do not sell to patients.
- CAS No.: 1360053-81-1
- Formula: C28H28FN5O6S
- Molecular Weight:581.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Spebrutinib besylate
More- Blood. 2016 Jun 23;127(25):3237-52. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Br J Pharmacol. 2019 Dec;176(23):4491-4509. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Stem Cell Reports. 2019 May 14;12(5):996-1006. [Abstract]
- Molecules. 2022 Dec 22;28(1):79. [Abstract]
- Sci Rep. 2026 Mar 20;16(1):14300. [Abstract]
- iScience. 2024 Sep 24;27(11):110961. [Abstract]
- ACS Pharmacol Transl Sci. 2025 Mar 12;8(4):917-931. [Abstract]
- R Soc Open Sci. 2019 Jun 5;6(6):190434. [Abstract]
- Leuk Res. 2020 Jan:88:106286. [Abstract]
- bioRxiv. 2025 Jun 22:2025.06.19.660637. [Abstract]
- bioRxiv. 2024 September 08.
- Heliyon. 2023 Jun 9;9(6):e17058. [Abstract]
- Methods Mol Biol. 2018:1711:351-398. [Abstract]
- Oncotarget. 2017 Nov 30;8(67):111386-111395. [Abstract]
- Patent. US20170333436A1.
Biological Activity
IC50: <0.5 nM (Btk)[1]
Spebrutinib (CC-292) is a covalent, highly selective, orally active inhibitor of Btk with IC50 value of 0.5 nM. Spebrutinib also less potently inhibits Yes, c-Src, Brk, Lyn, and Fyn with IC50s of 723 nM, 1.729 μM, 2.43 μM, 4.4 μM, and 7.15 μM, rspectively. Extensive analysis has revealed that the EC50 of Btk occupancy from a Spebrutinib dose-response in Ramos cells (EC50=6 nM) correlated directly with the cellular EC50 of Btk kinase inhibition with Spebrutinib (EC50=8 nM). Furthermore, the concentration at which Spebrutinib inhibits 90% of Btk activity in Ramos cells is 35 nM while the concentration of Spebrutinib required for 90% occupancy of Btk is 39 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1360053-81-1
-
Molecular Weight 581.62
-
Formula C28H28FN5O6S
-
SMILES
COCCOC1=CC=C(NC2=NC=C(F)C(NC3=CC=CC(NC(C=C)=O)=C3)=N2)C=C1.O=S(C4=CC=CC=C4)(O)=O
-
Synonyms
AVL-292 benzenesulfonate; CC-292 besylate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Blood
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. [Abstract]2016 Jun 23;127(25):3237-52. PMID: 27143257 -
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Br J Pharmacol
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies. [Abstract]2019 Dec;176(23):4491-4509. PMID: 31364164 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Stem Cell Reports
2019 May 14;12(5):996-1006. PMID: 31031187 -
Molecules
A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma-Application to a Pharmacokinetic Study. [Abstract]2022 Dec 22;28(1):79. PMID: 36615272 -
Sci Rep
2026 Mar 20;16(1):14300. PMID: 41862552 -
iScience
Inhibition of proteolytic and ATPase activities of the proteasome by the BTK inhibitor CGI-1746. [Abstract]2024 Sep 24;27(11):110961. PMID: 39759071 -
ACS Pharmacol Transl Sci
Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures. [Abstract]2025 Mar 12;8(4):917-931. PMID: 40242575 -
R Soc Open Sci
A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation. [Abstract]2019 Jun 5;6(6):190434. PMID: 31312501 -
Leuk Res
Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. [Abstract]2020 Jan:88:106286. PMID: 31865062 -
bioRxiv
2025 Jun 22:2025.06.19.660637. PMID: 40666940 -
-
Heliyon
Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS: In vitro and in silico metabolic study. [Abstract]2023 Jun 9;9(6):e17058. PMID: 37484253 -
Methods Mol Biol
2018:1711:351-398. PMID: 29344898 -
Oncotarget
Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. [Abstract]2017 Nov 30;8(67):111386-111395. PMID: 29340061 -
Protocol
Cells are incubated in serum-free RPMI media for 1-1.5 hours. Isolated human B cells are incubated with Spebrutinib at a final concentration of 0.001, 0.01, 0.1 and 1 μM. Ramos cells are incubated with 0.1 nM-3 μM Spebrutinib. Cells are then incubated in the presence of compound for 1 hour at 37°C. Following incubation, cells are centrifuged and resuspended in 100 μL of serum-free RPMI and BCR is stimulated with addition of 5 μg/mL α-human IgM. Samples are centrifuged, washed in phosphate-buffered saline (PBS), and lysed in 100 μL of Cell Extraction Buffer plus 1:10 (v/v) PhosSTOP Phosphatase Inhibitor and 1:10 (v/v) Complete Protease Inhibitor. Antibodies used for immunoblot analysis include P-PLCγ2, PLCγ2 (3871; CST), Syk (2712; CST), P-Syk (2710; CST), Btk, P-Btk, and Tubulin. Membranes are scanned on a Li-Cor Odyssey scanner using infrared fluorescence detection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)